PetMed Express (NASDAQ:PETS) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

PetMed Express, Inc. (NASDAQ:PETS) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.33 and traded as high as $4.50. PetMed Express shares last traded at $4.48, with a volume of 327,233 shares changing hands.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of PetMed Express from a “buy” rating to a “hold” rating in a research report on Tuesday, February 11th.

PetMed Express Stock Up 5.4 %

The company has a 50-day moving average of $5.02 and a 200 day moving average of $4.33. The stock has a market capitalization of $92.56 million, a PE ratio of 448.45 and a beta of 0.70.

PetMed Express (NASDAQ:PETS) last released its earnings results on Monday, February 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). PetMed Express had a return on equity of 0.37% and a net margin of 0.14%. As a group, equities analysts predict that PetMed Express, Inc. will post 0.19 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Leslie C.G. Campbell bought 15,000 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was bought at an average cost of $5.38 per share, for a total transaction of $80,700.00. Following the acquisition, the director now directly owns 70,000 shares in the company, valued at $376,600. This represents a 27.27 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PETS. Arrowstreet Capital Limited Partnership grew its holdings in shares of PetMed Express by 26.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 513,381 shares of the company’s stock valued at $2,474,000 after purchasing an additional 107,614 shares during the period. Metavasi Capital LP grew its stake in shares of PetMed Express by 48.5% in the 4th quarter. Metavasi Capital LP now owns 340,302 shares of the company’s stock valued at $1,640,000 after buying an additional 111,194 shares during the period. Geode Capital Management LLC increased its holdings in shares of PetMed Express by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 224,788 shares of the company’s stock worth $1,084,000 after buying an additional 3,558 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of PetMed Express by 2.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 216,812 shares of the company’s stock valued at $1,045,000 after buying an additional 4,410 shares during the period. Finally, Man Group plc lifted its holdings in PetMed Express by 5.5% in the fourth quarter. Man Group plc now owns 145,796 shares of the company’s stock valued at $703,000 after acquiring an additional 7,646 shares during the last quarter. Hedge funds and other institutional investors own 73.33% of the company’s stock.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.